AKT1 and adrenal carcinoma: Stelcer et al. reported that exposure to Adropin in HAC15 adrenal carcinoma cell lines stimulates long-lasting proliferation through AKT-mediated pathways, with the proliferative effect being completely abolished by PI3K/AKT inhibitors [38].